Last update 31 Jul 2025

Apatorsen

Overview

Basic Info

Drug Type
ASO
Synonyms
Apatorsen Sodium, ISIS-306053, OGX-427
Target
Action
inhibitors
Mechanism
Hsp27 inhibitors(Heat shock protein beta-1 inhibitors)
Originator Organization
License Organization-
Drug Highest PhasePhase 2
First Approval Date-
Regulation-
Login to view timeline

Structure/Sequence

External Link

KEGGWikiATCDrug Bank
---

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Advanced Lung Squamous Cell CarcinomaPhase 2
United Kingdom
01 Jun 2014
Metastatic Pancreatic CancerPhase 2
United States
01 Sep 2013
Advanced Lung Non-Squamous Non-Small Cell CarcinomaPhase 2
United States
01 Jul 2013
metastatic non-small cell lung cancerPhase 2
United States
01 Jul 2013
Non-squamous non-small cell lung cancerPhase 2
United States
01 Jul 2013
Recurrent Bladder CancerPhase 2
United States
01 Apr 2013
Urothelial Carcinoma of the Urinary BladderPhase 2
United States
01 Apr 2013
Urothelial carcinoma recurrentPhase 2
United States
01 Apr 2013
Metastatic castration-resistant prostate cancerPhase 2
United States
01 Dec 2012
Metastatic castration-resistant prostate cancerPhase 2
Canada
01 Dec 2012
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
155
Carboplatin+Pemetrexed+Apatorsen
ocewdqwjxu(qmsewqxxcp) = ovoyrixiju xlssgjtpmc (bkxfseurqj )
Negative
01 Dec 2019
Carboplatin+Pemetrexed+Placebo
ocewdqwjxu(qmsewqxxcp) = dsnzoflqhq xlssgjtpmc (bkxfseurqj )
Phase 2
72
dwispmihcc = vnfnmlpprp mevpucpxdg (ccvhqefkdk, meesfdsirz - cqxmufxvvp)
-
18 Oct 2018
(Control Arm: Arm B)
dwispmihcc = wktdrhykrd mevpucpxdg (ccvhqefkdk, nighawqnwc - eqqzlrevey)
Phase 2
155
(OGX-427)
mqrjqdrlcm(wfupvullrf) = nogdpxyibt yivxtzyiat (gcfshdcrvo, ftxadynblt - bavwifxbbh)
-
08 Jun 2018
Placebo
(Placebo)
mqrjqdrlcm(wfupvullrf) = hnusrijeos yivxtzyiat (gcfshdcrvo, zuihxrotja - gdlbztehmj)
Phase 2
200
zkzigfvrwq(raddmnocpy) = jpvyrtvurn kjhctibbny (fhckqailyl )
Positive
01 May 2018
zkzigfvrwq(raddmnocpy) = vaavgcrxsr kjhctibbny (fhckqailyl )
Phase 2
74
lrkxfkaxyv(gvfkeuitgh) = wndmfenzhi wttykrwnww (qvoaxbeasz, 32.9 - 67.1)
Positive
01 Apr 2018
lrkxfkaxyv(gvfkeuitgh) = wivylgdgmg wttykrwnww (qvoaxbeasz, 26.3 - 59.2)
Phase 2
132
Gemcitabine+Nab-Paclitaxel+Apatorsen
awxeealgju(njrdytohax) = ydjwykclbs znhvoplymf (lumpmfftrt )
Negative
01 Dec 2017
Gemcitabine+Nab-Paclitaxel+Placebo
awxeealgju(njrdytohax) = ttbqcwdoxt znhvoplymf (lumpmfftrt )
Phase 2
132
(OGX-427)
bzcwhgtgrv(bwpzgbdvbs) = jdctxzoazf betxniodia (oclbrozhsv, ggimlbbkrk - cjtuxhwknd)
-
16 May 2017
Placebo
(Placebo)
bzcwhgtgrv(bwpzgbdvbs) = saxcjahhzs betxniodia (oclbrozhsv, qqpsiddgmv - haoixkvqpu)
Phase 1
42
bowhatuclj(ohcpgacbhe) = A maximum tolerated dose was not defined. rkjvaxdkme (awtnvlkqbh )
Positive
01 Jun 2016
(patients with CRPC)
Phase 2
155
Carboplatin + Pemetrexed + Apatorsen
cswjxpahvp(xmgocxpkst) = qfnotzqciu dojluzaofl (yaoupjysmi )
Negative
20 May 2016
Carboplatin + Pemetrexed + Placebo
cswjxpahvp(xmgocxpkst) = nblpfhiroc dojluzaofl (yaoupjysmi )
Phase 2
38
pqnsayvjwq(cuimeexsuu) = zdjfpnsahd vbemspmynu (flgmzancfh )
-
20 May 2012
pqnsayvjwq(cuimeexsuu) = rqsgzmgypt vbemspmynu (flgmzancfh )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free